Taisha HALTED and reOPEN -25%
Update Neurogene:
Neurogene Announces First Patient Dosed in High-Dose Cohort of NGN-401 Gene Therapy Clinical Trial for Rett Syndrome
High-dose NGN-401 has been well-tolerated, and low-dose NGN-401 continues to show a favorable safety profile
Interim safety data presented at the International Rett Syndrome Foundation (IRSF) ASCEND Summit
https://ir.neurogene.com/news-relea...-first-patient-dosed-high-dose-cohort-ngn-401
Taisha HALTED and reOPEN -25% Update Neurogene: Neurogene...
-
- There are more pages in this discussion • 13 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add NEU (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$19.91 |
Change
-0.030(0.15%) |
Mkt cap ! $2.544B | |||
| Open | High | Low | Value | Volume |
| $19.95 | $20.00 | $19.50 | $8.294M | 417.3K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 443 | $19.87 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $19.91 | 917 | 2 |
View Market Depth
| Last trade - 16.10pm 20/06/2024 (20 minute delay) ? |
| NEU (ASX) Chart |